Analysts Insights on Achillion Pharmaceut (ACHN)

Xavier Trudeau
Juin 22, 2017

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded up 4.03% during midday trading on Wednesday, reaching $13.68.

For investors, Forward P/E ratio allows a quick snapshot of the company's finances without getting bogged down in the details of an accounting report.

Many analysts have provided their estimated foresights on Achillion Pharmaceuticals, Inc.

Institutional investors now hold around $431 million or 89.6% in ACHN stock. Commerzbank Aktiengesellschaft FI increased its position in Achillion Pharmaceuticals by 1.4% in the fourth quarter. Sanders James Douglas sold $898,749 worth of stock or 45,000 shares. City Financial Investment Co Ltd boosted its stake in Valeant Pharmaceuticals International by 6.8% in the first quarter.

The company maintained ROI for the last twelve months at -16.20%. Creative Planning increased its stake in shares of Achillion Pharmaceuticals by 2.0% in the first quarter.

Taking a broader look at the analyst consensus, according to 8 analysts Hornbeck Offshore Services (NYSE:HOS)'s price will reach at $5.5 during 52 weeks. Finally, Warren Averett Asset Management LLC boosted its position in Valeant Pharmaceuticals International by 14.0% in the first quarter. Deschutes Portfolio Strategy LLC now owns 25,430 shares of the biopharmaceutical company's stock valued at $107,000 after buying an additional 3,000 shares during the last quarter.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings results on Tuesday, May 9th. Cambridge Advisors Inc. now owns 12,650 shares of the specialty pharmaceutical company's stock worth $140,000 after buying an additional 75 shares during the period. "(VRX) Raised to Strong-Buy at Vetr Inc." was published by Markets Daily and is the property of of Markets Daily. The company's stock has a normal trading capacity of 1.48M shares while the relative volume is 1.29.

In terms of Incyte Corporation (INCY) stock price comparison to its moving averages, shares of company are 6.97% away from the 50-day moving average and 6.67% away from 20-day average. The stock's market capitalization is $583.81 million. Achillion Pharmaceuticals has a 1-year low of $3.15 and a 1-year high of $10.06. (NASDAQ:ACHN). Fmr Lc invested 0% of its portfolio in Achillion Pharmaceuticals, Inc. The company beat the analyst EPS Estimate with the difference of $0.01. During the same period in the prior year, the business posted ($0.13) earnings per share.

Achillion Pharmaceuticals, Inc. reported its EPS as $-0.14 with the analysts projecting the EPS of the stock as $-0.15. Leerink Partners raised its rating on Achillion Pharmaceuticals, Outperform on 18/05/2017 in a reversal from its prior Mkt Perform rating. After this purchase, 3,500 common shares of ACHN are directly owned by the insider, with total stake valued at $15,785. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & worldwide trademark and copyright laws. The original version of this report can be read at

Several research analysts recently commented on the company. Robert W. Baird lifted their price objective on Achillion Pharmaceuticals from $5.00 to $10.00 and gave the company an "outperform" rating in a report on Monday, April 24th. They issued a "buy" rating and a $18.00 price objective for the company. Analysts reported that the Price Target for Achillion Pharmaceuticals, Inc. might touch $13 high while the Average Price Target and Low price Target is $7 and $5 respectively. Argus Research initiated National Grid plc (ADR) (NYSE:NGG) on Thursday, April 7 with "Hold" rating. Zacks Investment Research cut shares of Achillion Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Wednesday, May 10th. The stock now has a consensus rating of "Buy" and a consensus price target of $9.22.

Achillion Pharmaceuticals, a biopharmaceutical company. The Firm is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Firm is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

D'autres rapports CampDesrEcrues

Discuter de cet article